World leading innovative drug discovery & development Our research and development teams utilize our cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS. Astex has built a rich product portfolio with multiple drugs in clinical development Latest from Astex 23 SEPTEMBER 2021 Astex Pharmaceuticals Presents Overall Survival Data From ASCERTAIN Phase 3 Study of Oral Hypomethylating Agent INQOVI® (decitabine and cedazuridine) in MDS and CMML at International Congress on Myelodysplastic Syndromes In the News 13 JANUARY 2021 Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program 12 JANUARY 2021 David Rees, Chief Scientific Officer, inducted to the Royal Society of Chemistry BMCS (Biological and Medicinal Chemistry Sector) Hall of Fame. Sustaining Innovation Innovative postdoctoral research fellowships Learn more Career Opportunities We seek to attract and retain talented individuals who are passionate about improving patient outcomes. Interactive Scientific Resources Explore 3D protein-ligand structures from recent Astex publications. Download software developed by Astex scientists. Learn more © Astex Pharmaceuticals All rights reserved Useful links Home Sitemap Privacy Policy Terms of Use Legal Member of the Otsuka Group We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok